Five years of sentinel node biopsy for melanoma: The St George's melanoma unit experience

British Journal of Plastic Surgery

Volumn 57, Issue 2, 2004, Pages 97-104

  Topping, Adam ^a   Dewar, Donald ^a   Rose, Victoria ^a   Cavale, Naveen ^a   Allen, Rosemary ^a   Cook, Martin ^b   Powell, Barry ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

Author keywords

Breslow thickness; Melanoma; Sentinel node biopsy

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; BODY REGIONS; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; FEMALE; HEMATOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; LYMPHADENECTOMY; LYMPHEDEMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; NEVUS; POPULATION RESEARCH; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY; SEX DIFFERENCE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; UNITED KINGDOM; WOUND DEHISCENCE;

EID: 1242352985     PISSN: 00071226     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bjps.2003.03.002     Document Type: Article

References (35)

1. Gershenwald J, Thompson W, Mansfield P, Balch C, Reintgen D, Ross M. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage 1 or 2 melanoma patients. J Clin Oncol 1999;17:976-83.
2. Balch C, Soong S, Milton G. A comparison of prognostic factors and surgical results in 1786 patients with localized (stage I) melanoma treated in Alabama, USA, and New South Wales, Australia. Ann Surg 1982;196(6):677-84.
3. Reintgen D, Cox E, McCarty K. Efficacy of elective lymph node dissection in patients with intermediate thickness primary melanoma. Ann Surg 1983;198(3):379-85.
4. Drepper H, Kohler C, Bastian B, Breuninger H, Brocker E-B, Tilgen W. Benefit of elective lymph node dissection in subgroups of melanoma patients: results of a multicenter study of 3616 patients. Cancer 1993;72(3):741-9.
5. Rompel R, Garbe C, Buttner P, Teichelmann K, Petres J. Elective lymph node dissection in primary malignant melanoma: a matched-pair analysis. Mel Res 1995;5(3): 189-94.
6. Veronesi U, Adamus J, Bandiera D, Brennhovd I, Caceres E, Cascinelli N, et al. Inefficacy of immediate node dissection in stage 1 melanoma of the limbs. N Engl J Med 1977;297: 627-30.
7. Cascinelli N, Morabito A, Santinami M, MacKie R, Belli F. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet 1998;351:793-6.
8. Sim F, Taylor W, Pritchard D, Soule E. Lymphadenectomy in the management of stage 1 malignant melanoma: a prospective randomised study. Mayo Clin Proc 1986;61: 697-705.
9. Balch C, Soong S, Bartolucci A, Urist M, Karakousis C, Smith T, et al. Efficacy of an elective regional lymph node dissection of 1-4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 1996;224:255-63.
10. Reintgen D, Cruse C, Wells K, Berman C, Fenske N, Lyman G. The orderly progression of melanoma nodal metastases. Ann Surg 1994;220:759-67.
11. Morton D, Wen D, Wong J, Economou J, Cagle L, Cochran A. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392-9.
12. Morton D, Wen D, Foshag L, Essner R, Cochran A. Intraoperative lymphatic mapping and selective cervical lymphadenectomy for earty-stage melanomas of the head and neck. J Clin Oncol 1993;11(9):1751-6.
13. Albertini J, Cruse C, Rapaport D, Wells K, Ross M, Reintgen D. Intraoperative radio-lympho-scintigraphy improves sentinel lymph node identification for patients with melanoma. Ann Surg 1996;223(2):217-24.
14. Morton D, Thompson J, Essner R, Elashoff R, Stern S, Cochran A. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for earty-stage melanoma: a multicentre trial. Multicentre Selective Lymphadenectomy Trial Group. Ann Surg 1999;230(4):453-63.
15. Otley C, Zitelli J. Review of sentinel lymph node biopsy and systemic interferon for melanoma: promising but investigational modalities. Dermatol Surg 2000;26:177-80.
16. Thomas J, Patocskai E. The argument against sentinel node biopsy for malignant melanoma: its use should be confined to patients in clinical trials. BMJ 2000;321:3-4.
17. McMasters, M, Reintgen D, Gershenwald J, Fenske N, Balch C, Coit D. Sentinel lymph node biopsy for melanoma: controversy despite widespread agreement. J Clin Oncol 2001; 19:2851-5.
18. Balch C, Buzaid A, Soong S-J, Atkins M, Cascinelli N, Thompson J. Final version of the American joint committee on cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19(16):3635-48.
19. WHO, WHO declares lymphatic mapping to be the standard of care for melanoma. Oncology 1999;13:288.
20. O'Toole G, Hettiaratchy S, Allan R, Powell B. Aberrant sentinel nodes in malignant melanoma. Br J Plast Surg 2000; 53(5):415-7.
21. Moloney D, Overstall S, Allan R, Powell B. An aberrant lymph node containing metastatic melanoma detected by sentinel node biopsy. Br J Plast Surg 2001;54(7):638-40.
22. Cochran A, Bailly C, Cook M, Crotty K, Mihm M, Mooi W, et al. Recommendations for the reporting of tissues removed as part of the surgical treatment of cutaneous melanoma. Association of Directors of Anatomic and Surgical Pathology. Hum Pathol 1997;28(10):1123-5.
23. Cochran A. The pathologists role in sentinel lymph node evaluation [Review]. Semin Nucl Med 2000;30(1):11-17.
24. Hettiaratchy S, Kang N, O'Toole G, Allan R, Cook M, Powell B. Sentinel lymph node biopsy in malignant melanoma: a series of 100 consecutive patients. Br J Plast Surg 2000;53: 559-62.
25. Gershenwald J, Colome M, Lee J, Mansfield P, Tseng C, Ross M. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 1998; 16(6):2253-60.
26. Cook M, Green M, Powell B. The development of optimal assessment of sentinel node biopsies for melanoma; 2002 (submitted for publication).
27. Muller M, Leeuwen Pv, Diest Pv, Vuylsteke R, Pijpers R, Meijer S. No indication for performing sentinel node biopsy in melanoma patients with a Breslow thickness of less than 0.9 mm. Mel Res 2001;11(3):303-7.
28. Mansson-Brahme E, Carstensen J, Erhardt K, Lagerlof B, Ringborg U, Rutqvist L. Prognostic factors in thin cutaneous malignant melanoma. Cancer 1994;73(9):2324-32.
29. Marghoob A, Koenig K, Bittencourt F, Kopf A, Bart R. Breslow thickness and Clark level in melanoma: support for including level in pathology reports and in American Joint Committee on Cancer Staging. Cancer 2000;88(3):491-6.
30. Balch C, Buzaid A, Atkins M, Morton D, Reintgen D, Gershenwald J, et al. A new American joint committee on cancer staging system for cutaneous melanoma. Cancer 2000;88:1484-91.
31. Balch C, Soong S-J, Gershenwald J, Thompson J, Reintgen D, Cascinelli N. Prognostic factors analysis of 17,600 melanoma patients: validation of the AJCC melanoma staging system. J Clin Oncol 2001;19(16):3622-34.
32. Blessing K, McLaren KM. Histological regression in primary cutaneous melanoma: recognition, prevalence and significance. Histopathology 1992;20:315-22.
33. Barnhill R, Fine J, Roush G, Berwick M. Predicting five-year outcome for patients with cutaneous melanoma in a population-based study. Cancer 1996;78:427-32.
34. Rayatt S, Hettiaratchy S, Key A, Powell B. Psychosocial benefits of sentinel node biopsy in the management of cutaneous malignant melanoma. Br J Plast Surg 2002;55(2): 95-9.
35. Crowley N, Seigler H. Relationship between disease-free interval and survival in patients with recurrent melanoma. Arch Surg 1992;127:1303.